Stay updated on RMC-6236 in RAS Mutant Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The site footer revision label was updated from Revision: v3.3.1 to Revision: v3.3.2.
    Difference
    0.0%
    Check dated 2025-12-01T16:19:15.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Editorial updates were made to the PubMed publication note on the Study Details page to clarify auto-fill from PubMed, and the Revision label was updated to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T12:00:13.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The page now describes a Phase 1/2 multicenter open-label study of RMC-6236 with dose escalation and expansion cohorts to establish MTD/RP2D, enrolling up to 754 participants; it also clarifies the drug as a RAS-MULTI(ON) inhibitor targeting KRAS, NRAS, and HRAS mutations.
    Difference
    0.8%
    Check dated 2025-11-17T06:19:01.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The study record content remains unchanged between versions, with only minor formatting differences observed in the screenshots. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T00:52:42.000Z thumbnail image
  6. Check
    72 days ago
    Change Detected
    Summary
    Page now includes an official operating-status notice and updates version to v3.2.0, replacing v3.1.0.
    Difference
    4%
    Check dated 2025-10-05T07:42:40.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    Update: page now lists a new contact number (1-844-273-8633) and the software revision as v3.1.0, replacing the previous v3.0.2.
    Difference
    0.1%
    Check dated 2025-09-28T02:55:51.000Z thumbnail image

Stay in the know with updates to RMC-6236 in RAS Mutant Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the RMC-6236 in RAS Mutant Solid Tumors Clinical Trial page.